心脉[Table_StockNameRptType] 医疗（688016） 公司点评 国内政策扰动明显，看好产品出海加速 [Table_Rank] 投资评级：买入（维持） | | | 2025 年 3 月 28 日，公司发布 2024 年年度报告。报告期内，公司实现营 业收入 12.06 亿元（同比+1.61%），归母净利润 5.02 亿元（同比+1.96%）， 扣非净利润 3.95 亿元（同比-14.43%）；单四季度，公司实现营业收入 2.37 亿元（同比-20.75%），归母净利润-0.51 亿元（同比-149.26%），扣 非净利润-1.06 亿元（同比-209.78%）。 ⚫ 点评： ⚫ 核心产品调价+集采轮流覆盖，国内市场承压 报告期内，公司 1Q/2Q/3Q/4Q 单季度分别实现营业收入 3.58/4.29/1.82/2.37 亿元，同比变动 25.4%/27.7%/-31.7%/-20.8%，2H24 承压明显，主要系核心产品价格调整、补缴税款及滞纳金所致。2024 年 9 月，公司主动脉覆膜支架系列产品在医保局的指导下进行了价格调 整，胸主动脉覆膜支架终端价下调约 40%及以上，腹主动脉覆膜 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience significant operational growth in 2024, driven by new business developments and a strong performance in Q4 2024, with revenue reaching a record high [7][8] - The company has successfully expanded into new projects, including the seating frame and railway container sectors, contributing to a robust revenue increase of 50% year-on-year in 2024 [7] - 2025 is anticipated to be a pivotal year for the company, with key advancements in its core business and the potential for substantial breakthroughs in the automotive seating market [7] Financial Performance Summary - For 2024, the company achieved operating revenue of 2,276 million yuan, a year-on-year increase of 49.9%, and a net profit attributable to the parent company of 137 million yuan, also up by 50.3% [6][7] - The projected financials for 2025-2027 indicate continued growth, with net profits expected to reach 220 million yuan in 2025, 328 million yuan in 2026, and 436 million yuan in 2027, reflecting growth rates of 60.7%, 48.8%, and 32.9% respectively [6][7] - The company's gross margin for 2024 was reported at 17.3%, with expectations for gradual improvement in subsequent years [6][7] Business Development Insights - The company has made significant progress in its R&D capabilities, particularly in the automotive seating sector, with a fully equipped laboratory and a team of experienced professionals [7] - Ongoing collaborations with several well-known automotive manufacturers are expected to enhance the company's market position and product offerings [7] - The successful launch of new products, such as railway containers, demonstrates the company's ability to diversify and innovate within its operational framework [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady business progress, with a recent acquisition of a hospital expanding its medical service footprint [5][15] - The company's 2024 annual performance met expectations, with revenue of 1.559 billion RMB, a year-on-year increase of 6.01%, and a net profit of 115 million RMB, up 14.92% [12] - The acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million RMB is expected to enhance the company's medical service capabilities [5][15] - The company is focusing on a dual-driven strategy in medical services and medical devices, anticipating continued growth in both sectors [20] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.559 billion RMB, with a net profit of 115 million RMB, and a significant increase in operating cash flow by 36.44% to 259 million RMB [12] - The medical services segment generated 1.192 billion RMB in revenue, a 3.76% increase, while the medical devices segment saw a 14.05% increase to 367 million RMB [12][6] - The company expects revenues of 1.821 billion RMB, 2.114 billion RMB, and 2.308 billion RMB for 2025, 2026, and 2027 respectively, with corresponding net profits of 136 million RMB, 161 million RMB, and 188 million RMB [20][9] Acquisition and Expansion - The acquisition of Changsha Kexin Tumor Hospital is projected to add significant value, with performance commitments ensuring net profits of 57 million RMB, 58 million RMB, and 60 million RMB for 2025 to 2027 [5][15] - The hospital is a comprehensive tumor specialty facility, which will enhance the company's service offerings and operational synergies [15] Strategic Outlook - The company is embracing AI in its operations, developing a three-tier AI+medical framework to enhance service delivery and operational efficiency [16] - The strategic focus on both organic growth and acquisitions in the medical services and devices sectors is expected to drive sustainable growth [20]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience significant operational growth in 2024, driven by new business developments and a strong performance in Q4 2024, with a record high quarterly revenue [7][8] - The company has successfully expanded into new projects, including the chair frame and railway container sectors, which are anticipated to contribute significantly to revenue [7] - 2025 is identified as a critical year for fundamental changes in the company, with expectations for breakthroughs in the automotive seating business [7] Financial Performance Summary - For 2024, the company achieved a revenue of 2,276 million yuan, representing a year-on-year increase of 49.9%, and a net profit attributable to the parent company of 137 million yuan, also up by 50.3% [6][7] - The projected revenues for 2025, 2026, and 2027 are 2,812 million yuan, 3,621 million yuan, and 4,511 million yuan, respectively, with growth rates of 23.5%, 28.8%, and 24.6% [6][7] - The net profit attributable to the parent company is expected to reach 220 million yuan in 2025, 328 million yuan in 2026, and 436 million yuan in 2027, with growth rates of 60.7%, 48.8%, and 32.9% respectively [6][7] Key Financial Metrics - The gross margin for 2024 is reported at 17.3%, with expectations to improve to 18.5% in 2025 [6][7] - Return on equity (ROE) is projected to increase from 8.3% in 2024 to 16.2% by 2027 [6][7] - The price-to-earnings (P/E) ratio is expected to decrease from 32.13 in 2024 to 13.36 in 2027, indicating a potential increase in valuation attractiveness over time [6][7]

[Table_StockNameRptType] 一拖股份（601038） 公司点评 盈利端短期承压，坚定看好出海+行业大型高端化 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-04-02 | | 570 收盘价（元） | 13.75 | | 近 12 个月最高/最低（元） | 20.49/13.03 | | 总股本（百万股） | 1123.65 | | 流通股本（百万股） | 731.71 | | 流通股比例（%） | 65.12 | | 总市值（亿元） | 154.50 | | 流通市值（亿元） | 100.61 | [公司价格与沪深 Table_Chart] 300 走势比较 -30% -20% -10% 0% 10% 20% 30% 一拖股份 沪深300 [分析师：张帆 Table_Author] 执业证书号：S0010522070003 邮箱：zhangfan@hazq.com 相关报告 ⚫ 投资建议 1.《国内农机领军者，立足中国，放眼 世界》2024-09-26 2.《业绩短期承压，看好未来长期发展》 2024-11-08 ...

[Table_StockNameRptType] 一拖股份（601038） 公司点评 1.《国内农机领军者，立足中国，放眼 世界》2024-09-26 2.《业绩短期承压，看好未来长期发展》 2024-11-08 主要观点： ⚫[Table_Summary] 公司发布 2024 年年报 盈利端短期承压，坚定看好出海+行业大型高端化 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-04-02 | | 570 收盘价（元） | 13.75 | | 近 12 个月最高/最低（元） | 20.49/13.03 | | 总股本（百万股） | 1123.65 | | 流通股本（百万股） | 731.71 | | 流通股比例（%） | 65.12 | | 总市值（亿元） | 154.50 | | 流通市值（亿元） | 100.61 | [公司价格与沪深 Table_Chart] 300 走势比较 -30% -20% -10% 0% 10% 20% 30% 一拖股份 沪深300 [分析师：张帆 Table_Author] 执业证书号：S001052207 ...

低空亮相消博，光伏迎来"小阳春" [Table_IndNameRptType] 电力设备 行业周报 [Table_IndRank] 行业评级：增持 报告日期： 2025-04-01 [Table_Chart] 行业指数与沪深 300 走势比较 -31% -19% -7% 5% 17% 29% 4/24 7/24 10/24 1/25 电力设备 沪深300 [Table_Author] 分析师：张志邦 执业证书号：S0010523120004 邮箱： zhangzhibang@hazq.com 分析师：刘千琳 执业证书号：S0010524050002 邮箱： liuqianlin@hazq.com [Table_Report] 相关报告 1.华安电新周报：海风项目稳步推 进，光伏组件再度涨价 2025-03-17 2.海风进入项目释放期，光伏组件小 幅涨价 2025-03-03 3.【华安电新】AIDC 电源报告：算 力浪潮起，电源擎动 AIDC 2025-02- 25 根据国家电网电子商务平台公示数据，特高压项目第一次设备招标推 荐候选人公示，合计中标金额 19.59 亿元，其中 1000kV 组合电器中 标 ...

[Table_Author] 首席分析师：颜子琦 执业证书号：S0010522030002 [Table_IndNameRptType]2 固定收益 点评报告 如何看待二季度国债发行计划？ 报告日期： 2025-04-01 电话：13127532070 邮箱：yanzq@hazq.com [Table_Author] 研究助理：洪子彦 主要观点： ⚫[Table_Summary] 2025Q2 国债发行计划落地，如何看待？ 2025Q2 国债发行计划落地，整体符合预期，我们先对发行计划进行拆解： 其次，两点变化值得关注，一是长债开始增发，二是注资特别国债的发行。 进一步，虽然结构上长债发行规模提升，但 4 月国债净融资压力不高。在当 前单券发行规模增加、活跃券持续时间拉长的背景下，我们假设二季度国债发 行的单券规模为初至今对应期限券种的发行均值，乘以相应期限债券发行数 量得到整体发行规模，二季度国债净融资高峰集中在 5-6 月，4 月由于到期量 较大供给压力不高。 整体而言，二季度开始国债供给压力逐步回升，结构变化上关键期限长债出 现增发，特别国债注资集中在 5-7Y，但 4 月国债到期量相对较大使得利率债 ...

Investment Rating - Investment Rating: Buy (Maintain) [3] Core Views - The company reported a significant increase in production and has committed to a higher dividend payout ratio [2] - For the fiscal year 2024, the company achieved revenue of 420.51 billion yuan, a year-on-year increase of 0.94%, and a net profit attributable to shareholders of 137.94 billion yuan, up 11.38% year-on-year [7] - The company has maintained a strong operational performance despite challenges such as asset impairment affecting profits [8] - The company has a leading position in the industry regarding reserve and production growth rates, with a capital expenditure of 132.7 billion yuan in 2024, the highest in its history [9] - The company is focused on shareholder returns, maintaining a high dividend payout ratio, with a total dividend of 1.40 Hong Kong dollars per share for 2024, a 12% increase year-on-year [12] - The company is expected to achieve net profits of 140.37 billion yuan, 146.32 billion yuan, and 154.52 billion yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 8.79, 8.44, and 7.99 [13] Financial Summary - For 2024, the company reported total revenue of 420.51 billion yuan, with a net profit of 137.94 billion yuan, and a basic earnings per share of 2.90 yuan [7][14] - The company’s gross margin is projected to be 53.6% for 2024, with a return on equity (ROE) of 18.5% [14] - The company’s total assets are expected to reach 1,056.28 billion yuan by 2024, with a debt-to-equity ratio of 29.0% [16]

Investment Rating - The investment rating for Agricultural Bank is "Buy" (maintained) [1] Core Views - Agricultural Bank's revenue and net profit growth rates are leading among state-owned banks, with 2024 revenue and net profit increasing by 2.26% and 4.72% year-on-year, respectively, marking an acceleration compared to the first three quarters of 2024 [4][9] - The bank's asset quality continues to improve, with a non-performing loan (NPL) ratio of 1.3% at the end of 2024, down 2 basis points from the previous quarter [8][9] - The bank is well-positioned to benefit from urban-rural integration and has a strong focus on county-level financial services, which is expected to drive growth [9] Summary by Sections Financial Performance - In 2024, Agricultural Bank's total assets, loans, and financial investments grew by 8.4%, 10.13%, and 23.5% year-on-year, respectively [5] - The bank's net interest income increased by 1.56% year-on-year, with a slight improvement in growth rate compared to the previous quarter [4] - Non-interest income saw a significant increase of 26.3% year-on-year, driven by strong performance in financial investments [4] Loan Growth - Agricultural Bank's total loan balance reached 23.98 trillion yuan, with corporate, personal, and discount loans growing by 10.6%, 9.35%, and 15% year-on-year, respectively [5] - Personal loans outperformed the national average growth rate, with personal consumption loans and personal business loans growing by 28.3% and 35% year-on-year [5] Asset Quality - The bank's NPL ratio decreased to 1.3%, with a coverage ratio of 299.61%, indicating a stable risk absorption capacity [8] - The bank's focus on county-level loans has resulted in a lower NPL ratio of 1.21% for these loans, which is better than the overall average [8][9] Investment Outlook - The bank is expected to see revenue and profit growth accelerate in 2024, maintaining its leadership among state-owned banks [9] - Projections for 2025-2027 indicate a slight decline in revenue growth in 2025, followed by a gradual recovery in subsequent years [9]